demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 all comersCOVID-19 mild to moderate
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderate
remdesivir SOLIDARITY ... NIH NIAID ACTT-1 Mahajan DisCoVeRy ... Norwegian NOR study ... Andreas ... GS-US-540-5774, 5 days GS-US-540-5773 ... GS-US-540-5774, 10 days

0 studies excluded by filtering options 0